nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

15.03.2018 | Original Article – Clinical Oncology

Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients’ prognosis

verfasst von: Larissa Dettmar, Nancy Ahmed, Matthias Kotzsch, Sandra Diersch, Rudolf Napieralski, Dalila Darmoul, Manfred Schmitt, Wilko Weichert, Marion Kiechle, Julia Dorn, Viktor Magdolen

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gene expression of a variety of the 15 members of the KLK serine protease family is dysregulated in ovarian cancer. We aimed at determining the clinical relevance of KLK13 and KLK14 mRNA expression in tumor tissues of a homogeneous patient cohort afflicted with advanced high-grade serous ovarian cancer (FIGO stage III/IV).

Methods

mRNA expression levels of KLK13 and KLK14 were assessed by quantitative PCR in tumor tissue of 91 patients and related with clinical factors and patients’ outcome.

Results

There was no significant association of KLK13 and KLK14 mRNA expression with the clinical factors ascitic fluid volume or residual tumor mass. In univariate Cox regression analysis, elevated KLK13 mRNA levels were significantly linked with shorter progression-free (PFS; hazard ratio [HR] = 1.97, P = 0.020) and overall survival (OS; HR = 1.81, P = 0.041). High KLK14 mRNA levels were significantly associated with prolonged PFS (HR = 0.44, P = 0.017) and showed a trend towards significance for OS (HR = 0.55, P = 0.070). In multivariable analysis, including the factors age, residual tumor mass, ascitic fluid volume, KLK13, and KLK14, both KLKs, apart from residual tumor mass, remained statistically independent predictive markers: patients with high KLK13 mRNA expression levels displayed a more than twofold increase risk for shorter PFS (HR = 2.14, P = 0.020) as well as OS (HR = 2.05, P = 0.028), whereas elevated KLK14 mRNA values were found to be significant for both, prolonged PFS (HR = 0.36, P = 0.007) and OS (HR = 0.46, P = 0.037).

Conclusion

These results indicate that in advanced high-grade serous ovarian cancer KLK13 may become proficient for tumor-supporting functions, whereas KLK14 may have adopted tumor-suppressing activity.

Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J, Boshoff C (2004) Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 90:686–692CrossRefPubMedPubMedCentral

Ahmed N, Dorn J, Napieralski R, Drecoll E, Kotzsch M, Goettig P, Zein E, Avril S, Kiechle M, Diamandis EP, Schmitt M, Magdolen V (2016) Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer. Biol Chem 397:1265–1276CrossRefPubMedPubMedCentral

Borgono CA, Diamandis EP (2004) The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4:876–890CrossRefPubMed

Borgono CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, Fracchioli S, Katsaros D, Diamandis EP (2003) Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 63:9032–9041PubMed

Borgono CA, Michael IP, Shaw JL, Luo LY, Ghosh MC, Soosaipillai A, Grass L, Katsaros D, Diamandis EP (2007) Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem 282:2405–2422CrossRefPubMed

Chang A, Yousef GM, Scorilas A, Grass L, Sismondi P, Ponzone R, Diamandis EP (2002) Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer 86:1457–1464CrossRefPubMedPubMedCentral

Chou R-H, Lin S-C, Wen H-C, Wu C-W, Chang W-SW (2011) Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation. Biochem Biophys Res Comm 409:442–447CrossRefPubMed

Dorn J, Bayani J, Yousef GM, Yang F, Magdolen V, Kiechle M, Diamandis EP, Schmitt M (2013) Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies. Thromb Haemost 110:408–422CrossRefPubMed

Dorn J, Beaufort N, Schmitt M, Diamandis EP, Goettig P, Magdolen V (2014) Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers. Crit Rev Clin Lab Sci 51:63–84CrossRefPubMed

Emami N, Diamandis EP (2008) Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin. J Biol Chem 283:3031–3041CrossRefPubMed

Fritzsche F, Gansukh T, Borgono CA, Burkhardt M, Pahl S, Mayordomo E, Winzer KJ, Weichert W, Denkert C, Jung K, Stephan C, Dietel M, Diamandis EP, Dahl E, Kristiansen G (2006) Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status. Br J Cancer 94:540–547CrossRefPubMedPubMedCentral

Gueugnon F, Barascu A, Mavridis K, Petit-Courty A, Marchand-Adam S, Gissot V, Scorilas A, Guyetant S, Courty Y (2015) Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer. Tumour Biol 36:4979–4986CrossRefPubMed

Hooper JD, Bui LT, Rae FK, Harvey TJ, Myers SA, Ashworth LK, Clements JA (2001) Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics 73:117–122CrossRefPubMed

Ishige S, Kasamatsu A, Ogoshi K, Saito Y, Usukura K, Yokoe H, Kouzu Y, Koike H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H, Uzawa K (2014) Decreased expression of kallikrein-related peptidase 13: possible contribution to metastasis of human oral cancer. Mol Carcinog 53:557–565CrossRefPubMed

Kapadia C, Chang A, Sotiropoulou G, Yousef GM, Grass L, Soosaipillai A, Xing X, Howarth DH, Diamandis EP (2003) Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem 49:77–86CrossRefPubMed

Konstantoudakis G, Florou D, Mavridis K, Papadopoulos IN, Scorilas A (2010) Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clin Biochem 43:1205–1211CrossRefPubMed

Kryza T, Silva ML, Loessner D, Heuzé-Vourc’h N, Clements JA (2016) The kallikrein-related peptidase family: dysregulation and functions during cancer progression. Biochimie 122:283–299CrossRefPubMed

Luo LY, Yousef G, Diamandis EP (2003) Human tissue kallikreins and testicular cancer. Apmis 111:225–232 discussion 232–233CrossRefPubMed

Paliouras M, Diamandis EP (2008) Intracellular signaling pathways regulate hormone-dependent kallikrein gene expression. Tumour Biol 29:63–75CrossRefPubMed

Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, Sotiropoulou G (2009) A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res 69:3779–3787CrossRefPubMed

Pampalakis G, Obasuyi O, Papadodima O, Chatziioannou A, Zoumpourlis V, Sotiropoulou G (2014) The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway. Oncotarget 5:2390–2403CrossRefPubMed

Papachristopoulou G, Avgeris M, Charlaftis A, Scorilas A (2011) Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues. Thromb Haemost 105:131–137CrossRefPubMed

Pfaffl W (2012) Quantification strategies in real-time polymerase chain reaction. In: Filion M (ed) “Quantitative real-time PCR in applied microbiology”. Caister Academic press, Norfolk, pp 53–61

Prassas I, Eissa A, Poda G, Diamandis EP (2015) Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov 14:183–202CrossRefPubMed

Prat J (2012) Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 460:237–249CrossRefPubMed

Prat J (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124:1–5CrossRefPubMed

Reid JC, Matsika A, Davies CM, He Y, Broomfield A, Bennett NC, Magdolen V, Srinivasan B, Clements JA, Hooper JD (2017) Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases. Am J Cancer Res 7:2257–2274PubMedPubMedCentral

Sanchez WY, de Veer SJ, Swedberg JE, Hong EJ, Reid JC, Walsh TP, Hooper JD, Hammond GL, Clements JA, Harris JM (2012) Selective cleavage of human sex hormone-binding globulin by kallikrein-related peptidases and effects on androgen action in LNCaP prostate cancer cells. Endocrinology 153:3179–3189CrossRefPubMed

Scarisbrick IA (2012) Physiological and pathophysiological roles of kallikrein-related peptidases in the central nervous system. In: Kallikrein-related peptidases: characterization, regulation, and interactions within the protease web, vol 1. de Gruyter, Berlin, pp 349–372

Scorilas A, Mavridis K (2014) Predictions for the future of kallikrein-related peptidases in molecular diagnostics. Expert Rev Mol Diagn 14:713–722CrossRefPubMed

Scorilas A, Borgono CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP (2004) Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J Clin Oncol 22:678–685CrossRefPubMed

Sher YP, Chou CC, Chou RH, Wu HM, Wayne Chang WS, Chen CH, Yang PC, Wu CW, Yu CL, Peck K (2006) Human kallikrein 8 protease confers a favorable clinical outcome in non-small cell lung cancer by suppressing tumor cell invasiveness. Cancer Res 66:11763–11770CrossRefPubMed

Talieri M, Li L, Zheng Y, Alexopoulou DK, Soosaipillai A, Scorilas A, Xynopoulos D, Diamandis EP (2009) The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer 100:1659–1665CrossRefPubMedPubMedCentral

Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, Lundberg E, Hober S, Nilsson P, Mattsson J, Schwenk JM, Brunnström H, Glimelius B, Sjöblom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F (2017) A pathology atlas of the human cancer transcriptome. Science 357:eaan2507CrossRefPubMed

White NM, Mathews M, Yousef GM, Prizada A, Popadiuk C, Dore JJ (2009a) KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br J Cancer 101:1107–1113CrossRefPubMedPubMedCentral

White NMA, Mathews M, Yousef GM, Prizada A, Fontaine D, Ghatage P, Popadiuk C, Dawson L, Doré JJE (2009b) Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone. Cancer Biomark 5:279–287CrossRefPubMed

White NM, Bui A, Mejia-Guerrero S, Chao J, Soosaipillai A, Youssef Y, Mankaruos M, Honey RJ, Stewart R, Pace KT, Sugar L, Diamandis EP, Dore J, Yousef GM (2010) Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. Biol Chem 391:411–423CrossRefPubMed

Yoon H, Blaber SI, Evans DM, Trim J, Juliano MA, Scarisbrick IA, Blaber M (2008) Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis. Protein Sci 17:1998–2007CrossRefPubMedPubMedCentral

Yoon H, Blaber SI, Debela M, Goettig P, Scarisbrick IA, Blaber M (2009) A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15. Biol Chem 390:373–377CrossRefPubMedPubMedCentral

Yousef GM, Diamandis EP (2003) Human kallikreins: common structural features, sequence analysis and evolution. Curr Genom 4:147–165CrossRef

Yousef GM, Chang A, Diamandis EP (2000) Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem 275:11891–11898CrossRefPubMed

Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP (2001) Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res 61:3425–3431PubMed

Yousef GM, Borgono CA, Scorilas A, Ponzone R, Biglia N, Iskander L, Polymeris ME, Roagna R, Sismondi P, Diamandis EP (2002) Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br J Cancer 87:1287–1293CrossRefPubMedPubMedCentral

Yousef GM, Fracchioli S, Scorilas A, Borgono CA, Iskander L, Puopolo M, Massobrio M, Diamandis EP, Katsaros D (2003a) Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol 119:346–355CrossRefPubMed

Yousef GM, Stephan C, Scorilas A, Ellatif MA, Jung K, Kristiansen G, Jung M, Polymeris ME, Diamandis EP (2003b) Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 56:287–292CrossRefPubMed

Zhang R, Shi H, Chen Z, Feng W, Zhang H, Wu K (2012) Effects of kallikrein-related peptidase 14 gene inhibition by small interfering RNA in ovarian carcinoma cells. Mol Med Rep 5:256–259CrossRefPubMed

Zheng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, Scorilas A, Kim NW, Wolfert RL, Simon I, Li L, Feng Z, Diamandis EP (2007) A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res 13:6984–6992CrossRefPubMed

Titel: Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients’ prognosis
verfasst von: Larissa Dettmar
Nancy Ahmed
Matthias Kotzsch
Sandra Diersch
Rudolf Napieralski
Dalila Darmoul
Manfred Schmitt
Wilko Weichert
Marion Kiechle
Julia Dorn
Viktor Magdolen
Publikationsdatum: 15.03.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2623-7

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients’ prognosis

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Impact of peri-operative blood transfusion on post-operative infections after radical gastrectomy for gastric cancer: a propensity score matching analysis focusing on the timing, amount of transfusion and role of leukocyte depletion

Combinational chromosomal aneuploidies and HPV status for prediction of head and neck squamous cell carcinoma prognosis in biopsies and cytological preparations

High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma

Ovarian metastasis in patients with endometrial cancer: risk factors and impact on survival

Predictors of recurrence and survival of pathological T1N0M0 invasive adenocarcinoma following lobectomy

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie